Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease

NCT04736628 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04736628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04736628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2021
Completion date
September 21, 2023
Enrollment
261 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease